Early combination treatment for AIDS is urgedBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7063.962 (Published 19 October 1996) Cite this as: BMJ 1996;313:962
Glimmers of hope are continuing to emerge in the fight against AIDS, as new trials show that combination antiretroviral treatment halves the rate of disease progression or death compared with treatment with a single drug.
Researchers from the US AIDS Clinical Trials Group Study have just reported that combination antiretroviral treatment delays progression of the disease to AIDS or death by 39–51% compared with zidovudine treatment alone (New England Journal of Medicine 1996;335:1081-90). The results came from a trial of more than 2400 patients infected with HIV-1 and with CD4 cell counts of 200—500 cells/ml who were randomly assigned to four regimens: zidovudine, zidovudine plus didanosine, zidovudine plus zalcitabine, or …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial